Please check your internet connection and try again.
# Urimax (Tamsulosin)
## Overview
Tamsulosin is a selective alpha-1 adrenergic receptor antagonist that preferentially blocks alpha-1A receptors in the prostate and bladder neck, causing smooth muscle relaxation and improved urinary flow.
## Primary Indications
* Signs and symptoms of Benign Prostatic Hyperplasia (BPH).
* Off-label: Medical expulsive therapy for distal ureteral stones.
## Adult Dosing
* **BPH:** 0.4 mg orally once daily, taken 30 minutes after the same meal each day. If no response after 2–4 weeks, may increase to 0.8 mg once daily.
* **Maximum Dose:** 0.8 mg daily.
## Pediatric Dosing
* **Safety/Efficacy:** Not established for pediatric use. Use is off-label and rare (occasionally used in specialized pediatric urology for non-neurogenic bladder/voiding dysfunction). Dosing is weight-based (typically 0.05 mg/kg to 0.1 mg/kg) but **must** be determined by a pediatric specialist.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** Use caution in severe hepatic impairment (Child-Pugh class C); not studied/not recommended.
* **CYP3A4/2D6 Inhibitors:** Avoid or exercise extreme caution when using with potent inhibitors (e.g., ketoconazole, ritonavir) due to risk of increased exposure.
## Contraindications
* Known hypersensitivity (e.g., angioedema, urticaria) to tamsulosin.
* Use with potent CYP3A4 inhibitors (e.g., ketoconazole).
## Adverse Effects
* **Common:** Dizziness, headache, ejaculation disorders (retrograde ejaculation), rhinitis, asthenia.
* **Serious:** Orthostatic hypotension, syncope (especially with the first dose), intraoperative floppy iris syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **Antihypertensives/PDE-5 Inhibitors:** May increase risk of symptomatic orthostatic hypotension.
* **Strong CYP3A4 Inhibitors (e.g., clarithromycin, ketoconazole):** Significantly increase tamsulosin serum levels.
* **Strong CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine):** May increase exposure; monitor for side effects.
## Monitoring
* Monitor blood pressure for hypotension/orthostasis.
* Assess symptom improvement or urinary flow rates during follow-up.
* Patients scheduled for cataract surgery should inform their ophthalmologist of current or past tamsulosin use.
## Clinical Pearls
* **Administration:** Must be taken as a whole capsule; do not crush, chew, or open the capsule, as this alters the controlled-release mechanism.
* **First-Dose Phenomenon:** If the patient stops therapy for several days, restart at the 0.4 mg dose.
* **Surgical Risk:** Tamsulosin is the most common cause of IFIS; surgeons should be notified before cataract or glaucoma procedures.
* **Baseline:** Rule out prostate cancer before initiating therapy.
***
*Educational Disclaimer: This information is for educational purposes and does not substitute professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors via reliable clinical databases (e.g., Lexicomp, UpToDate) before prescribing or administering medication.*
